Hildegard Greinix

Hildegard Greinix

Auto-generated profile, based on publicly available information

Hildegard Greinix

Division of Hematology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
MJMateja Kralj Juric
Mateja Kralj Juric
SGSakhila Ghimire
Sakhila Ghimire
JOJustyna Ogonek
Justyna Ogonek
EWEva M. Weissinger
Eva M. Weissinger
EHErnst Holler
Ernst Holler
HGHildegard T. Greinix
Hildegard T. Greinix
Since the early beginnings, in the 1950’s, hematopoietic stem cell transplantation (HSCT) has become an established curative treatment for an increasing number of patients with life-threatening hematological, oncological, hereditary and immunological diseases. This has become possible due to worldwide efforts of preclinical and clinical research focusing on issues of transplant immunology, reduction of transplant-associated morbidity and mortality and efficient malignant disease eradication. The latter has been accomplished by potent graft-versus-leukemia effector cells contained in the stem cell graft. Exciting insights into the genetics of the human leukocyte antigen (HLA) system allowed improved donor selection , including HLA-identical related and unrelated donors. Besides bone marrow (BM) other stem cell sources like G-CSF-mobilized peripheral blood stem cells and cord blood stem cells have been established in clinical routine. Use of reduced-intensity or non-myeloablative conditioning regimens has been associated with a marked reduction of non-hematological toxicities and eventually, non-relapse mortality allowing older patients and individuals with comorbidities to undergo allogeneic HSCT and to benefit from graft-versus-leukemia or anti-tumour effects. Whereas in the early years malignant disease eradication by high-dose chemotherapy or radiotherapy was the ultimate goal, nowadays allogeneic HSCT has been recognized as cellular immunotherapy relying prominently on immune mechanisms and to a lesser extent on non-specific direct cellular toxicity. This chapter will summarise the key milestones of HSCT and introduce current developments.

Verified
Journal Article
Open access
PDF file
KPKatrin Pansy
Katrin Pansy
BUBarbara Uhl
Barbara Uhl
Jelena KrsticJelena Krstic
Jelena Krstic
MSMarta Szmyra
Marta Szmyra
KFKaroline Fechter
Karoline Fechter
ADAlexander Deutsch
Alexander Deutsch
The tumor microenvironment (TME) is a critical regulator of tumor growth, progression, and metastasis. Since immune cells represent a large fraction of the TME, they play a key role in mediating pro- and anti-tumor immune responses. Immune escape, which suppresses anti-tumor immunity, enables tumor cells to maintain their proliferation and growth. Numerous mechanisms, which have been intensively studied in recent years, are involved in this process and based on these findings, novel immunotherapies have been successfully developed. Here, we review the composition of the TME and the mechanisms by which immune evasive processes are regulated. In detail, we describe membrane-bound and soluble factors, their regulation, and their impact on immune cell activation in the TME. Furthermore, we give an overview of the tumor/antigen presentation and how it is influenced under malignant conditions. Finally, we summarize novel TME-targeting agents, which are already in clinical trials for different tumor entities.

1 April 2011 in Vaccine
Verified
Journal Article
Closed access
IHInken Hilgendorf
Inken Hilgendorf
MFMathias Freund
Mathias Freund
WJWolfgang Jilg
Wolfgang Jilg
HEHermann Einsele
Hermann Einsele
JGJuan Gea-Banacloche
Juan Gea-Banacloche
RMRoland Meisel
Roland Meisel

24 June 2021 in Haematologica
Verified
Journal Article
Open access
PDF file
HGHildegard T. Greinix
Hildegard T. Greinix
DEDirk-Jan Eikema
Dirk-Jan Eikema
LKLinda Koster
Linda Koster
OPOlaf Penack
Olaf Penack
IYIbrahim Yakoub-Agha
Ibrahim Yakoub-Agha
NKNicolaus Kröger
Nicolaus Kröger
Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether the incidence and mortality of aGvHD have decreased over time. 102,557 patients with a median age of 47.6 years and with malignancies after first allogeneic sibling or unrelated donor (URD) transplant were studied in the following periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. Findings: 100-day incidences of aGvHD grades II-IV decreased from 40% to 38%, 32%, 29% and 28%, respectively, over calendar time (P<0.001). In multivariate analysis URD, not in complete remission (CR) at transplant or untreated, and female donor for male recipient were factors associated with increased risk whereas the use of ATG/alemtuzumab decreased aGvHD incidence. Median follow-up was 214, 169, 127, 81 and 30 months, respectively, for the periods analyzed. Three-year-survival after aGvHD grades II-IV increased significantly from 38% to 40%, 43%, 44%, and 45%, respectively. In multivariate analysis URD, not in CR at transplant, peripheral blood as stem cell source, female donor for male recipient, and the use of ATG/alemtuzumab were associated with increased mortality whereas reduced-intensity conditioning was linked to lower mortality. Mortality increased with increasing patient age but decreased in the recent cohorts. Our analysis demonstrates that aGvHD has decreased over recent decades and also that the survival rates of patients affected with aGvHD has improved.

1 September 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
ZDZachariah DeFilipp
Zachariah DeFilipp
DCDaniel R. Couriel
Daniel R. Couriel
ALAleksandr Lazaryan
Aleksandr Lazaryan
VBVijaya Raj Bhatt
Vijaya Raj Bhatt
NBNataliya P. Buxbaum
Nataliya P. Buxbaum
HGHildegard T. Greinix
Hildegard T. Greinix
Positive results from recent clinical trials have significantly expanded current therapeutic options for patients with chronic graft-versus-host disease (GVHD). However, new insights into the associations between clinical characteristics of chronic GVHD, pathophysiologic mechanisms of disease, and the clinical and biological effects of novel therapeutic agents are required to allow for a more individualized approach to treatment. The current report is focused on setting research priorities and direction in the treatment of chronic GVHD. Detailed correlative scientific studies should be conducted in the context of clinical trials to evaluate associations between clinical outcomes and the biological effect of systemic therapeutics. For patients who require systemic therapy but not urgent initiation of glucocorticoids, clinical trials for initial systemic treatment of chronic GVHD should investigate novel agents as monotherapy without concurrently starting glucocorticoids, to avoid confounding biological, pathological, and clinical assessments. Clinical trials for treatment-refractory disease should specifically target patients with incomplete or suboptimal responses to most recent therapy who are early in their disease course. Close collaboration between academic medical centers, medical societies, and industry is needed to support an individualized, biology-based strategic approach to chronic GVHD therapy.

24 September 2022 in Leukemia
Verified
Journal Article
Open access
PDF file
HGHildegard T. Greinix
Hildegard T. Greinix
FAFrancis Ayuk
Francis Ayuk
RZRobert Zeiser
Robert Zeiser
Patients with steroid-refractory graft-versus-host disease (GvHD) are known to have a poor prognosis and for decades no approved drug has been available to treat this serious condition. Although ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor demonstrated significantly higher response rates in randomized trials compared to the best available therapy, and thus, is of benefit in both acute as well as chronic GvHD, there is an urgent medical need to improve results, such as durability of responses, response in eye, liver and lung manifestations and reduction of infectious complications. In this “Review” article we would like to offer strategies for improving treatment results in patients with steroid-refractory GvHD by combining ruxolitinib with extracorporeal photopheresis (ECP), a leukapheresis-based immunomodulatory treatment frequently applied in T-cell mediated immune disease including GvHD. Our article explores key published evidence supporting the clinical efficacy of both ruxolitinib and ECP in the treatment of GvHD and highlights their potentially complementary mechanisms of action.